BioLineRx (NASDAQ:BLRX) Earns Hold Rating from Analysts at StockNews.com

StockNews.com initiated coverage on shares of BioLineRx (NASDAQ:BLRX) in a report published on Friday morning. The firm issued a hold rating on the biotechnology company’s stock.

Separately, HC Wainwright reduced their price target on BioLineRx from $21.00 to $9.00 and set a “buy” rating for the company in a research report on Monday, November 25th.

BioLineRx Price Performance

NASDAQ BLRX opened at $0.27 on Friday. The company has a market cap of $21.89 million, a PE ratio of -1.24 and a beta of 1.39. BioLineRx has a 52-week low of $0.19 and a 52-week high of $1.58. The company has a debt-to-equity ratio of 2.11, a quick ratio of 1.37 and a current ratio of 1.52. The firm’s 50 day moving average price is $0.32 and its 200-day moving average price is $0.52.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in BLRX. CVI Holdings LLC purchased a new stake in BioLineRx in the second quarter valued at about $462,000. PVG Asset Management Corp purchased a new position in shares of BioLineRx in the 2nd quarter valued at approximately $70,000. Finally, Atria Investments Inc boosted its stake in BioLineRx by 27.9% in the 3rd quarter. Atria Investments Inc now owns 133,974 shares of the biotechnology company’s stock worth $72,000 after purchasing an additional 29,193 shares in the last quarter. 1.56% of the stock is currently owned by hedge funds and other institutional investors.

BioLineRx Company Profile

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.